According to Orexo, the United States Patent and Trademark Office (USPTO) has issued the company US patent No. 11,737,980 (“Pharmaceutical composition for drug delivery”) which provides protection for OX640 epinephrine nasal powder. Orexo notes that it also received a European patent covering OX640 in 2022. The company announced Phase 1 results for OX640 in October 2022.
Orexo President and CEO Nikolaj Sørensen commented, “OX640 is truly a unique and innovative new product to be used for the emergency treatment of allergic reactions. I am pleased that this innovation has been recognized by the USPTO, an important step towards making this life-saving medication available for patients in the US. OX640 has shown astonishing chemical stability, impressive clinical data, and has significant global market potential. The strong patent portfolio covering OX640 is clearly a valuable asset to Orexo.”
Read the Orexo press release.
